Orforglipron maintains weight loss in trial
- Eli Lilly and Nature Medicine detailed a Phase 3b trial showing oral orforglipron helped people keep off weight after stopping injectable GLP-1 drugs. - After switching from Wegovy, participants on orforglipron kept all but 0.9 kg of prior weight loss over a year; after Zepbound, 5.0 kg. (nature.com) - That matters because long-term obesity care often breaks on convenience, cost, and adherence — and a pill changes the tradeoff. (nature.com)
Obesity drugs work well at taking weight off. The harder part is keeping it off once treatment changes, insurance shifts, or people simply get tired of injections. That gap is why this new orforglipron result matters. Eli Lilly and researchers published a Phase 3b trial on May 13 showing that people who switched from injectable GLP-1 drugs to Lilly’s once-daily oral pill mostly held on to the weight loss they had already earned. (nature.com) ### What is orforglipron? Orforglipron is Lilly’s small-molecule GLP-1 pill, sold in the U.S. as Foundayo after FDA approval on April 1, 2026. (nature.com) The big practical difference is that it is a daily pill rather than a weekly injection, and Lilly says it can be taken without food or water restrictions. That makes it a very different kind of maintenance option from Wegovy or Zepbound, even though all of them work through the same broad appetite-and-metabolism pathway. ### What was the new trial testing? This was not a “can the drug cause weight loss from scratch?” study. It asked a more specific question: if someone already lost weight on an injectable incretin drug, can they switch to a pill and avoid the usual rebound? The trial, called ATTAIN-MAINTAIN, followed adults with obesity or overweight plus related health problems for 52 weeks after they transitioned from a maximum tolerated dose of semaglutide or tirzepatide to either orforglipron or placebo. ### How much weight did people keep off? (medical.lilly.com) The cleanest number is the semaglutide group. People who switched from Wegovy to orforglipron maintained all but 0.9 kg of their prior weight loss on average over one year. The tirzepatide group did give back more, but still kept most of the benefit — participants switching from Zepbound to orforglipron maintained all but 5.0 kg of prior weight loss on average. Lilly also said the pill beat placebo on the primary and all key secondary endpoints. (nature.com) ### Did anything besides weight improve? Yes — and this is important because obesity drugs are really about risk reduction, not just the scale. The paper reports improvements versus placebo in waist circumference and several cardiometabolic markers, including blood pressure, lipids, and high-sensitivity C-reactive protein. Basically, the maintenance effect was not just cosmetic. The broader metabolic profile held up too. ### Why is switching so hard? Because the biology pushes back. When people stop or interrupt obesity treatment, appetite tends to rise and the body defends the higher weight it used to have. (biospace.com) That is why “I already lost the weight” is not the end of the story. Maintenance is its own phase of treatment, and it often falls apart when the original drug is expensive, hard to tolerate, hard to access, or simply burdensome to stay on. (nature.com) ### Why does a pill change the picture? A pill is not automatically better than an injection. But it is easier for a lot of people to start, easier to travel with, and psychologically simpler to stay on for years. That matters in a chronic disease where long-term adherence is half the battle. If a daily pill can preserve most of the benefit from a stronger injectable, doctors get a new step-down option — a bit like moving from a heavy-duty tool to a lighter one once the hardest work is done. ### Is this available now? (biospace.com) In the U.S., yes. Lilly’s medical information page says Foundayo was approved on April 1, 2026 and is now available through LillyDirect, telehealth providers, and retail pharmacies. The catch is that the maintenance-switching use described in ATTAIN-MAINTAIN is about how clinicians may use the drug in practice, not a separate consumer headline by itself. ### Bottom line? The real news is not that GLP-1 drugs help with weight loss — everyone knows that now. (nature.com) The news is that Lilly may have shown a workable off-ramp from injections without giving up most of the gains. If that holds up in everyday care, orforglipron could become less of a “weight-loss pill” story and more of a long-term maintenance story. (medical.lilly.com)
